Literature DB >> 27115731

Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.

J Shapiro1, D van Klaveren2, S M Lagarde1,3, E L A Toxopeus1, A van der Gaast4, M C C M Hulshof5, B P L Wijnhoven1, M I van Berge Henegouwen3, E W Steyerberg2, J J B van Lanschot1.   

Abstract

BACKGROUND: The value of conventional prognostic factors is unclear in the era of multimodal treatment for oesophageal cancer. This study aimed to quantify the impact of neoadjuvant chemoradiotherapy (nCRT) and surgery on well established prognostic factors, and to develop and validate a prognostic model.
METHODS: Patients treated with nCRT plus surgery were included. Multivariable Cox modelling was used to identify prognostic factors for overall survival. A prediction model for individual survival was developed using stepwise backward selection. The model was internally validated leading to a nomogram for use in clinical practice.
RESULTS: Some 626 patients who underwent nCRT plus surgery were included. In the multivariable model, only pretreatment cN category and ypN category were independent prognostic factors. The final prognostic model included cN, ypT and ypN categories, and had moderate discrimination (c-index at internal validation 0·63).
CONCLUSION: In patients with oesophageal or oesophagogastric cancer treated with nCRT plus surgery, overall survival can best be estimated using a prediction model based on cN, ypT and ypN categories. Predicted survival according to this model showed only moderate correlation with observed survival, emphasizing the need for new prognostic factors to improve survival prediction.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27115731     DOI: 10.1002/bjs.10142

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  11 in total

1.  Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators.

Authors:  Riccardo Lemini; Tamara Díaz Vico; Denslow A Trumbull; Kristopher Attwood; Aaron C Spaulding; Enrique F Elli; Dorin T Colibaseanu; Moshim Kukar; Emmanuel Gabriel
Journal:  J Gastrointest Oncol       Date:  2021-10

2.  The Evaluation of a SEER-Based Nomogram in Predicting the Survival of Patients Treated with Neoadjuvant Therapy Followed by Esophagectomy.

Authors:  Qing Wang; Zhiyong Sun; Xin Xu; Xiumei Ma; Xiaojing Zhao; Qing Ye
Journal:  Front Surg       Date:  2022-06-29

3.  Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer.

Authors:  G Jomrich; M Paireder; A Gleiss; I Kristo; L Harpain; S F Schoppmann
Journal:  Gastroenterol Res Pract       Date:  2017-06-27       Impact factor: 2.260

4.  Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.

Authors:  S R Markar; B J Noordman; H Mackenzie; J M Findlay; P R Boshier; M Ni; E W Steyerberg; A van der Gaast; M C C M Hulshof; N Maynard; M I van Berge Henegouwen; B P L Wijnhoven; J V Reynolds; J J B Van Lanschot; G B Hanna
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 5.  Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis.

Authors:  H G van den Boorn; E G Engelhardt; J van Kleef; M A G Sprangers; M G H van Oijen; A Abu-Hanna; A H Zwinderman; V M H Coupé; H W M van Laarhoven
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

6.  Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.

Authors:  E R C Hagens; M L Feenstra; W J Eshuis; M C C M Hulshof; H W M van Laarhoven; M I van Berge Henegouwen; S S Gisbertz
Journal:  Br J Surg       Date:  2020-02-03       Impact factor: 6.939

7.  Nomogram predicts survival benefit for non- metastatic esophageal cancer patients who underwent preoperative radiotherapy.

Authors:  Kenan Xie; Song Liu; Jianjun Liu
Journal:  Cancer Manag Res       Date:  2018-09-18       Impact factor: 3.989

8.  Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT.

Authors:  Lucas Goense; Jelle P Ruurda; Brett W Carter; Penny Fang; Linus Ho; Gert J Meijer; Richard van Hillegersberg; Wayne L Hofstetter; Steven H Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-16       Impact factor: 9.236

9.  A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.

Authors:  Tianyan Ding; Cantong Liu; Binliang Huang; Lingyu Chu; Laifeng Wei; Yiwei Lin; Yun Luo; Biao Zhang; Chaoqun Hong; Yiwei Xu; Yuhui Peng
Journal:  Cancer Manag Res       Date:  2021-10-09       Impact factor: 3.989

10.  Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma.

Authors:  Sarah Schumacher; Christoph Bartenhagen; Martin Hoffmann; Daniel Will; Johannes C Fischer; Stephan E Baldus; Christian Vay; Georg Fluegen; Levent Dizdar; Daniel Vallböhmer; Christoph A Klein; Wolfram T Knoefel; Nikolas H Stoecklein; Birte Möhlendick
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.